Your first 90 days
Your first 90 days on Elelyso for Gaucher disease
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Elelyso is a long-term schedule of IV infusions, one every other week, with a dose your doctor sets from your weight. On that schedule the first 90 days hold 7 infusions. This page lays out that stretch from the FDA label, Pfizer's Gaucher Personal Support program and one insurer's written rules.
What has to happen before the first bottle ships
Elelyso has no REMS, so the first infusion waits on a confirmed diagnosis, an insurance approval and a healthcare setting ready for allergic reactions. These are the 6 things in the way, in order.
A confirmed diagnosis of type 1
The label covers people 4 years and older with a confirmed diagnosis of type 1 Gaucher disease.
- Safety and effectiveness have not been established in children younger than 4.FDA label
Your current weight
The dose is counted in units per kilogram of actual body weight.
- Your weight sets how many vials are mixed for each infusion.FDA label
Your Cerezyme dose, if you are switching
For people on a stable Cerezyme (imiglucerase) dose, the label says to start Elelyso at the same units/kg dose.
- Your doctor decides whether a switch is acceptable.FDA label
A call or a form to Pfizer GPS
Pfizer tells doctors to start a patient by calling GPS at 1-855-353-5976 or by faxing a Treatment Request Form.
- A GPS Case Manager then becomes your main contact.Pfizer patient support offerings page
The insurance check
Pfizer says GPS can help verify your insurance benefits and explain what prior authorization the plan requires.
- GPS can also give information about the appeals process.Pfizer GPS page
Where the first infusion will happen
The label says to start Elelyso in a healthcare setting with equipment to restart breathing and the heart.
- A healthcare provider who knows how to manage anaphylaxis should supervise it.FDA label
The days that matter
Counted from the first infusion, on the label's schedule of one infusion every other week. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.GPS enrollment and the insurance check
Your doctor's office contacts GPS, and a Case Manager helps check your insurance.
- No source sets how long this takes, because each insurer works on its own timeline.
Approval, then booking the first infusion
Once the plan approves, the first infusion can be booked in a healthcare setting that is ready to treat a severe allergic reaction, as the label requires.
First infusion
A healthcare provider who knows how to treat anaphylaxis supervises the infusion, which takes 60 to 120 minutes.
- The label says to watch patients closely during and after the infusion.
Infusion 2
Infusions repeat every other week.
- The label says doctors may consider allergy medicines or steroids beforehand to lower the risk of an allergic reaction.
Infusion 3
Adults start at an infusion speed of 1.2mL a minute.
- After a person is shown to tolerate Elelyso, the label allows up to 2.2mL a minute.
Infusion 4
Pfizer says GPS can work with your infusion center so that Elelyso and supplies are on site.
- The aim is to cut waiting time when you arrive for an infusion.
Infusion 5
Pfizer says GPS can ask your insurer whether you have home-health benefits.
- If the insurer approves, GPS can contact a specialty pharmacy to set up at-home infusions.
Infusion 6
In the main adult trial, 17 of 32 people (53%) formed antibodies to Elelyso.
- The label says to watch people with these antibodies closely for allergic reactions.
Infusion 7
This is the seventh infusion counted from day 1.
- In the main adult trial, spleen and liver size and blood counts were measured at 9 months, past this point.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Elelyso label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated December 29, 2025, read from the FDA's label database today. FDA label
- December 2025
The pregnancy and breastfeeding sections were updated with registry data. They now say available data have not shown a drug-related risk of major birth defects or miscarriage.FDA letter
- January 2025
The allergic reaction warning changed how long to watch patients. It had said to observe for 3 hours after the start of each infusion, and now says during and after the infusion.FDA letter
- July 2024
The label gained a boxed warning for severe allergic reactions, including anaphylaxis, as part of an FDA change for enzyme replacement therapies as a group. Elelyso must now be started in a healthcare setting with emergency equipment.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- A dose set by weight
For people new to enzyme therapy, the labeled dose is 60 units/kg of actual body weight every other week.
- The label lets the doctor adjust the dose to each person's treatment goals.FDA label
- Switching from Cerezyme
If a switch from a stable Cerezyme dose is acceptable, the label says to start Elelyso at the same units/kg dose.
- Infusions then continue every other week.FDA label
- How the dose is mixed
Each vial holds 200 units of powder, mixed with sterile water and then added to salt water.
- The number of vials is rounded up to the next whole vial.FDA label
- Infusion time
The label gives an infusion time of 60 to 120 minutes and a minimum of 60 minutes.
- A filter in the IV line is required.FDA label
- Infusion speed for children
Children under 30kg (about 66 lb) get 1mL a minute.
- Children at 30kg or more start at 1mL a minute and may later go up to 2mL a minute.FDA label
- Watching after the infusion
The current label says to watch patients closely during and after the infusion.
- Until January 2025 it said to watch for 3 hours after the start of each infusion.FDA-approved label, July 2024
- Medicines before an infusion
To lower the risk of allergic reactions, the label says doctors may consider antihistamines, steroids or both before an infusion.
- Your doctor decides what you or your child gets.FDA label
- If a reaction happens
For a mild reaction, staff may slow or pause the infusion or give allergy, fever or steroid medicines.
- For a severe one, the label says to stop Elelyso and treat at once.FDA label
- After a severe reaction
The label asks the doctor to weigh the risks and benefits of giving Elelyso again.
- It calls for caution if treatment is restarted.FDA label
- If an infusion is missed
The label gives no missed-dose instructions.
- Its schedule is one infusion every other week, and your doctor decides what happens after a missed one.FDA label
- Pregnancy
Registry data and safety reports have not shown a drug-related risk of major birth defects or miscarriage.
- The label says untreated type 1 Gaucher disease carries its own risks in pregnancy.FDA label
- Breastfeeding
No data show whether Elelyso passes into breast milk.
- Registry data have not shown side effects in breastfed babies.
- The label says to weigh the benefits of breastfeeding against the mother's need for Elelyso.FDA label
- Children under 4
The label says safety and effectiveness have not been established in children younger than 4 years.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of anaphylaxis
Hives, low blood pressure, flushing, wheezing, chest tightness, nausea, vomiting and dizziness.
- The label says to get medical care right away if symptoms of a life-threatening reaction occur.FDA label
Anaphylaxis can come late in treatment
The boxed warning says anaphylaxis has happened early in treatment and after long use.
- If it happens, the label says to stop Elelyso and treat it at once, including with epinephrine.FDA label
Other allergic reactions
Itching, swelling under the skin, flushing, redness, rash, nausea, vomiting, cough, chest tightness and throat irritation.
- In trials these came during the infusion and up to 3 hours after it started.FDA label
How often reactions happened
In trials, 21 of 72 people (29%) had an allergic reaction, and 2 of them had signs of anaphylaxis.
- People in the trials were not routinely given allergy medicines beforehand.FDA label
Vomiting in children
Vomiting was more common in children, affecting 4 of 9 children new to treatment.
- The label says it may be a symptom of an allergic reaction.FDA label
Antibodies and allergy
Allergic reactions occurred in 36% of people who formed antibodies to Elelyso and 15% of those who did not.
- The label says to watch people with antibodies closely.FDA label
Other side effects
In adults new to treatment, the most common were headache (19%) and joint pain (13%).
- Tiredness, nausea and dizziness each affected 9%, and people who switched also reported arm or leg pain (10%).FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP Blue policy below asks for a diagnosis of type 1 Gaucher disease and an age of 4 years or older. Pfizer says GPS can explain a plan's prior authorization requirements.FEP Blue policy
- The request is for another type of Gaucher diseaseFEP Blue treats Elelyso as investigational for anything other than type 1. The label also covers only type 1 Gaucher disease.FEP Blue policy
- The patient is younger than 4FEP Blue requires an age of 4 years or older. The label says safety and effectiveness have not been established in younger children.FEP Blue policy
- Also taking another Gaucher medicineFEP Blue does not allow Elelyso together with Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa. Your doctor decides which treatment fits you.FEP Blue policy
- The approval has run outFEP Blue approves Elelyso for 2 years at a time. Renewal uses the same requirements as the first approval.FEP Blue policy
- A copay you cannot payPfizer Gaucher Personal Support (1-855-353-5976) can explain current co-pay help for people with commercial insurance. On November 11, 2026, the co-pay terms on Pfizer's patient page still showed an offer that expired on December 31, 2024.Pfizer GPS page
- Co-pay terms that look out of dateThe co-pay terms posted on Pfizer's patient page set a yearly limit and list an expiry date of December 31, 2024. This page gives no dollar figure for that reason, and GPS can say what applies now.Pfizer GPS page
- Medicare, Medicaid or other government insuranceThe co-pay terms posted on Pfizer's page exclude state and federally funded insurance. Pfizer says Elelyso may be available at no cost to qualified government-insured people through the Pfizer Patient Assistance Program.Pfizer GPS page
- No insuranceThe co-pay terms posted on Pfizer's page are not valid for cash-paying patients. The Pfizer Patient Assistance Program may provide Elelyso at no cost to qualified uninsured people who meet its financial rules.Pfizer GPS page
- You live in MassachusettsThe co-pay terms on Pfizer's page for healthcare professionals exclude Massachusetts residents whose prescriptions are covered by third party insurance. Those terms list an expiry date of December 31, 2023, and GPS can confirm what applies now.Pfizer access and support page for professionals
- The plan denies coveragePfizer says GPS can provide information about the insurance coverage appeals process. GPS also offers support when your insurance changes.Pfizer GPS page
FEP Blue (Blue Cross and Blue Shield Federal Employee Program) prior authorization policy, April 1, 2026
- Age 4 years or older
- A diagnosis of Gaucher disease, type 1
- No dual therapy with another medicine for type 1 Gaucher disease (Cerdelga, Cerezyme, VPRIV, Zavesca or Yargesa)
- Any other use is considered investigational
- Renewal uses the same requirements
Approval length. 2 years.
This policy (5.85.014) was last reviewed on March 6, 2026 and cites the December 2025 label, the current one. It lists no specialist, lab report or dose limit among its requirements. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A GPS Case Manager as the main contact for patients, parents and caregivers
- Help with insurance benefits verification, prior authorization requirements, the appeals process and insurance changes
- Co-pay help for eligible people with commercial insurance, through GPS. The terms posted on Pfizer's page list an expiry date of December 31, 2024, and GPS can explain what is offered now
- Under the posted terms, co-pay help is not open to people on Medicare, Medicaid, TRICARE, Veterans Affairs health care or other state or federal insurance, or to cash-paying patients
- The Pfizer Patient Assistance Program, Elelyso at no cost for qualified uninsured or government-insured people who meet financial rules and live in the US
- A list of infusion sites in your area, and coordination so that Elelyso and supplies are at the site
- A check of home-health benefits with your insurer, and contact with a specialty pharmacy to set up at-home infusions if the insurer approves
- Help researching transportation to and from infusions. GPS does not give the infusions itself
- A Pfizer co-pay FAQ dated March 2024 lists GPS phone hours as Monday to Friday, 8 AM to 6 PM Eastern. It also says co-pay enrollment renews automatically each year if you still qualify PfizerCopay.com FAQs
Details as the drugmaker publishes them. Pfizer GPS page
Five questions for the pharmacist or the support line
- Who orders my Elelyso for each infusion, and where is it shipped?
- Is my dose based on my current weight, and who do I tell if my weight or my child's weight changes?
- How many vials make up my dose, and how long will my infusion run?
- Will I get any medicine before my infusion, and why or why not?
- How long will I be watched after each infusion?
- If I move to home infusion, who brings the medicine and who watches me during the infusion?
- Is any Pfizer co-pay help being applied to my bill?
Questions people ask in the first weeks
How long does an Elelyso infusion take?
The label gives 60 to 120 minutes, with a minimum of 60 minutes. Adults start at 1.2mL a minute, and children start at 1mL a minute. The label also says to watch patients closely during and after the infusion.
How often will I get Elelyso?
Every other week. For people new to enzyme therapy, the labeled dose is 60 units/kg of actual body weight. The label lets the doctor adjust the dose to each person's treatment goals.
Can I switch from Cerezyme to Elelyso?
The label describes it. If a switch from a stable Cerezyme dose is acceptable, Elelyso starts at the same units/kg dose every other week. In a 9-month trial of 31 people who switched, 30 needed no dose change. Your doctor decides.
Can I get Elelyso at home?
Not at first. The label says to start Elelyso in a healthcare setting with emergency equipment. Pfizer says GPS can check your home-health benefits and, if your insurer approves, contact a specialty pharmacy to set up at-home infusions.
Will I get medicine before my infusion?
Possibly. To lower the risk of allergic reactions, the label says doctors may consider antihistamines, steroids or both beforehand. People in the trials were not routinely given these medicines. Your doctor decides what you get.
Does Elelyso have a boxed warning?
Yes. Since July 2024 the label has carried a boxed warning for severe allergic reactions, including anaphylaxis. The FDA asked for this change on enzyme replacement therapies as a group.
Can young children receive Elelyso?
The label covers children 4 years and older with type 1 Gaucher disease. It says safety and effectiveness have not been established in children younger than 4.
How long does it take to start Elelyso after it is prescribed?
There is no fixed number of days. The insurance check, prior authorization and booking an infusion site each take their own time. A Pfizer GPS Case Manager can help with the insurance steps.
Free email alert
Hear when the Elelyso label changes
One email the day the FDA revises the Elelyso label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Elelyso only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Gaucher disease for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - ELELYSO- taliglucerase alfa injection, powder, lyophilized, for solution (updated December 29, 2025, SPL version 31, prescribing information revised 12/2025), Pfizer Laboratories Div Pfizer Inc, via DailyMed, December 29, 2025.
- ELELYSO (taliglucerase alfa) for injection, for intravenous use, prescribing information, revised 7/2024, FDA, Drugs@FDA, July 10, 2024.
- Pfizer GPS | ELELYSO® (taliglucerase alfa) for injection | Risk Info, Pfizer, January 1, 2025.
- Resources | ELELYSO® (taliglucerase alfa) for injection | Safety Info (Access and Support for ELELYSO Patients), Pfizer, January 1, 2026.
- Patient Support Offerings | Pfizer for Professionals, Pfizer, January 1, 2026.
- PfizerCopay.com Frequently Asked Questions (FAQs) (PP-BEQ-USA-0061, March 2024), Pfizer, March 1, 2024.
- Elelyso, FEP pharmacy policy 5.85.014, Blue Cross Blue Shield Association, Federal Employee Program, April 1, 2026.
- BLA 022458/S-034 supplement approval letter, updates to subsections 8.1 Pregnancy and 8.2 Lactation, FDA, December 22, 2025.
- BLA 022458/S-033 supplement approval letter, change to the observation time for anaphylactic reactions in subsection 5.1, FDA, January 17, 2025.
- BLA 022458/S-031 supplement approval letter, enzyme replacement therapy class safety labeling change for hypersensitivity, FDA, July 10, 2024.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing geneticist. Found an error? Use the report link in the footer and it will be checked against the source.